St. Jude Enters $350 Mil. U.S. Stented Tissue Valve Market With Biocor
This article was originally published in The Gray Sheet
Executive Summary
St. Jude Medical expects to reverse the long decline of its heart valve sales in the second half of 2005 with FDA approval of the Biocor stented tissue valves, announced Aug 8